<?xml version='1.0' encoding='utf-8'?>
<document id="24641107"><sentence text="Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro."><entity charOffset="0-11" id="DDI-PubMed.24641107.s1.e0" text="Domperidone" /><entity charOffset="27-39" id="DDI-PubMed.24641107.s1.e1" text="pioglitazone" /><entity charOffset="53-64" id="DDI-PubMed.24641107.s1.e2" text="ondansetron" /><pair ddi="false" e1="DDI-PubMed.24641107.s1.e0" e2="DDI-PubMed.24641107.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s1.e0" e2="DDI-PubMed.24641107.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s1.e0" e2="DDI-PubMed.24641107.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24641107.s1.e1" e2="DDI-PubMed.24641107.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s1.e1" e2="DDI-PubMed.24641107.s1.e2" /></sentence><sentence text="Domperidone (prokinetic agent) is frequently co-administered with pioglitazone (anitidiabetic) or ondansetron (antiemetic) in gastroparesis management"><entity charOffset="0-11" id="DDI-PubMed.24641107.s2.e0" text="Domperidone" /><entity charOffset="66-78" id="DDI-PubMed.24641107.s2.e1" text="pioglitazone" /><entity charOffset="98-109" id="DDI-PubMed.24641107.s2.e2" text="ondansetron" /><pair ddi="false" e1="DDI-PubMed.24641107.s2.e0" e2="DDI-PubMed.24641107.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s2.e0" e2="DDI-PubMed.24641107.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s2.e0" e2="DDI-PubMed.24641107.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24641107.s2.e1" e2="DDI-PubMed.24641107.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s2.e1" e2="DDI-PubMed.24641107.s2.e2" /></sentence><sentence text=" These drugs are metabolized via cytochome P-450 (CYP) 3A4, raising the possibility of interaction and adverse reactions" /><sentence text=" The concentration-dependent inhibitory effect of pioglitazone and ondansetron on domperidone hydroxylation was monitored in pooled human liver microsomes (HLM)"><entity charOffset="50-62" id="DDI-PubMed.24641107.s4.e0" text="pioglitazone" /><entity charOffset="67-78" id="DDI-PubMed.24641107.s4.e1" text="ondansetron" /><entity charOffset="82-93" id="DDI-PubMed.24641107.s4.e2" text="domperidone" /><pair ddi="false" e1="DDI-PubMed.24641107.s4.e0" e2="DDI-PubMed.24641107.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s4.e0" e2="DDI-PubMed.24641107.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s4.e0" e2="DDI-PubMed.24641107.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24641107.s4.e1" e2="DDI-PubMed.24641107.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s4.e1" e2="DDI-PubMed.24641107.s4.e2" /></sentence><sentence text=" Pioglitazone was further assessed as a mechanism-based inhibitor"><entity charOffset="1-13" id="DDI-PubMed.24641107.s5.e0" text="Pioglitazone" /></sentence><sentence text=" Microsomal binding was evaluated in our assessment" /><sentence text=" In HLM, Vmax/Km estimates for monohydroxy domperidone formation decreased in presence of pioglitazone"><entity charOffset="31-54" id="DDI-PubMed.24641107.s7.e0" text="monohydroxy domperidone" /><entity charOffset="90-102" id="DDI-PubMed.24641107.s7.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.24641107.s7.e0" e2="DDI-PubMed.24641107.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s7.e0" e2="DDI-PubMed.24641107.s7.e1" /></sentence><sentence text=" Diagnostic plots indicated that pioglitazone inhibited domperidone in a partial mixed-type manner"><entity charOffset="33-45" id="DDI-PubMed.24641107.s8.e0" text="pioglitazone" /><entity charOffset="56-67" id="DDI-PubMed.24641107.s8.e1" text="domperidone" /><pair ddi="false" e1="DDI-PubMed.24641107.s8.e0" e2="DDI-PubMed.24641107.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s8.e0" e2="DDI-PubMed.24641107.s8.e1" /></sentence><sentence text=" The in vitro Ki was 1" /><sentence text="52 µM" /><sentence text=" Predicted in vivo AUCi/AUC ratio was 1" /><sentence text="98" /><sentence text=" Pioglitazone also exerted time-dependent inhibition on the metabolism of domperidone and the average remaining enzymatic activity decreased significantly upon preincubation with pioglitazone over 0-40 min"><entity charOffset="1-13" id="DDI-PubMed.24641107.s13.e0" text="Pioglitazone" /><entity charOffset="74-85" id="DDI-PubMed.24641107.s13.e1" text="domperidone" /><entity charOffset="179-191" id="DDI-PubMed.24641107.s13.e2" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.24641107.s13.e0" e2="DDI-PubMed.24641107.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s13.e0" e2="DDI-PubMed.24641107.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s13.e0" e2="DDI-PubMed.24641107.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24641107.s13.e1" e2="DDI-PubMed.24641107.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24641107.s13.e1" e2="DDI-PubMed.24641107.s13.e2" /></sentence><sentence text=" Diagnostic plots showed no inhibitory effect of ondansetron on domperidone hydroxylation"><entity charOffset="49-60" id="DDI-PubMed.24641107.s14.e0" text="ondansetron" /><entity charOffset="64-75" id="DDI-PubMed.24641107.s14.e1" text="domperidone" /><pair ddi="false" e1="DDI-PubMed.24641107.s14.e0" e2="DDI-PubMed.24641107.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s14.e0" e2="DDI-PubMed.24641107.s14.e1" /></sentence><sentence text=" 6" /><sentence text=" In conclusion, pioglitazone inhibited domperidone metabolism in vitro through different complex mechanisms"><entity charOffset="16-28" id="DDI-PubMed.24641107.s16.e0" text="pioglitazone" /><entity charOffset="39-50" id="DDI-PubMed.24641107.s16.e1" text="domperidone" /><pair ddi="false" e1="DDI-PubMed.24641107.s16.e0" e2="DDI-PubMed.24641107.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24641107.s16.e0" e2="DDI-PubMed.24641107.s16.e1" /></sentence><sentence text=" Our in vitro data predict that the co-administration of these drugs can potentially trigger an in vivo drug-drug interaction" /><sentence text="" /></document>